SCI 발표논문

SCI 발표논문

← SCI 발표논문 목록

J Interv Cardiol. 2020;2020:3872704.

Safety and Efficacy of Second-Generation Drug-Eluting Stents in Real-World Practice: Insights from the Multicenter Grand-DES Registry.

, , , , , , , ,

제1저자 기유정 · 교신저자 박경우

PMID 32180687 PMC7061140 DOI 10.1155/2020/3872704 IF 1.4 순환기내과
소속 (1)
  1. Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul 03080, Republic of Korea.

Abstract

OBJECTIVE In this study, we sought to compare the efficacy and safety of the Xience Prime/Xience V/Promus EES and Biomatrix/Biomatrix Flex/Nobori BES with resolute integrity/resolute ZES using the grand drug-eluting stent (Grand-DES) registry.

BACKGROUND Currently, new-generation drug-eluting stents (DESs) are used as the standard of care in patients undergoing percutaneous coronary intervention. No study has simultaneously compared everolimus-eluting stent (EES), biolimus-eluting stent (BES), and zotarolimus-eluting stent (ZES).

METHODS Stent-related composite outcomes (target lesion failure) and patient-related composite outcomes were compared in crude and propensity score-matched analysis.

RESULTS Of the 17,286 patients in the Grand-DES group, 5,137, 2,970, and 4,990 patients in the EES, BES, and ZES groups completed a three-year follow-up. In the propensity score-matched cohort, the stent-related outcome (EES vs. BES vs. ZES; 5.9% vs. 6.7% vs. 7.1%, P = 0.226) and patient-related outcomes (12.7% vs. 13.5% vs. 14.3%, P = 0.226) and patient-related outcomes (12.7% vs. 13.5% vs. 14.3%, P = 0.226) and patient-related outcomes (12.7% vs. 13.5% vs. 14.3%, P = 0.226) and patient-related outcomes (12.7% vs. 13.5% vs. 14.3%.

CONCLUSIONS In this robust real-world registry with unrestricted use of EES, BES, and ZES, the three stent groups showed comparable safety and efficacy at the 3-year follow-up.

Copyright © 2020 You-Jeong Ki et al.

Figures

Figure 1
Figure 1 Flow diagram of participants. Grand-DES registry includes 5 multicenter registries—HOST-biolimus-3000-Korea, HOST-Excellent-Prime, EXCELLENT prospective cohort, HOST-Resolinte, and Resolute-Korea—that enrolled all-comers treated with ≥1 DES. DES = drug-eluting stent; EES = everolimus-eluting stent; BES = biolimus-eluting stent; ZES = zotarolimus-eluting stent.
Figure 2
Figure 2 Survival analysis. Primary and major secondary outcomes in matched population. EES = everolimus-eluting stent; BES = biolimus-eluting stent; ZES = zotarolimus-eluting stent.
Figure 3
Figure 3 Survival analysis. Primary and major secondary outcomes in crude population. EES = everolimus-eluting stent; BES = biolimus-eluting stent; ZES = zotarolimus-eluting stent.
Figure 4
Figure 4 Survival curve of TLR. Differences in TLR divided by whether angiography was performed. (a) Group with dedicated angiography and (b) group without dedicated angiography. TLR = target lesion revascularization.

그림 출처: PubMed Central 공개 논문 (PMC7061140)

Conflict of interest statement

There are no conflicts of interest.

그 밖의 정보
출판 형태
Journal Article
저널
Journal of interventional cardiology · eISSN 1540-8183
전자 출판
2020-02-26
MeSH
Drug-Eluting Stents* / adverse effects / standards · Equipment Safety · Everolimus / pharmacology · Female · Humans · Immunosuppressive Agents / pharmacology · Male · Middle Aged · Percutaneous Coronary Intervention / adverse effects / instrumentation / methods · Propensity Score · Registries / statistics & numerical data · Sirolimus / analogs & derivatives / pharmacology · Treatment Outcome
Substances
Immunosuppressive Agents · Everolimus · zotarolimus · Sirolimus
참고문헌
21편